SCHEMBL19670597

SCHEMBL19670597

CCN1CC[C@@H](C)N(C(=O)Nc2ccccn2)c2nc(Cl)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.40
▸ PTGS1 P23219 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ DRD2 P14416 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ TRPV1 Q8NER1 1/20 0.38
▸ GRM5 P41594 3/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NOS2 P35228 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ CHRNA7 P36544 1/20 0.36
▸ CHRNA10 Q9GZZ6 1/20 0.36
▸ CHRNA9 Q9UGM1 1/20 0.36
▸ FGFR4 P22455 1/20 0.36
▸ CACNA1G O43497 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19365370 0.87 PTGS1 (0.41) NPC1PTGS1PTGS2DRD2DRD4
SCHEMBL19670184 0.84 MDM2 (0.39) NPC1PTGS1PTGS2DRD4GRM5
SCHEMBL19670244 0.82 HTR2A (0.45) CACNA1GCACNA1HCACNA1I
SCHEMBL16775803 0.82 FGFR4 (0.48) NPC1TRPV1GRM5MEN1KMT2A
SCHEMBL19706154 0.79 PTGS1 (0.40) NPC1PTGS1PTGS2DRD2DRD4
SCHEMBL19365644 0.78 TRPV1 (0.43) PTGS1PTGS2DRD2DRD4DRD3
SCHEMBL19670006 0.78 KARS1 (0.40) NPC1TRPV1CHRNA7CHRNA10CHRNA9
SCHEMBL19670291 0.77 CACNA1G (0.36) NPC1HTTRAB9ACACNA1GCACNA1H
SCHEMBL19865031 0.77 CNR2 (0.46) NPC1DRD4GRM5LMNATSHR
SCHEMBL19670187 0.77 MTOR (0.36) NPC1PTGS1PTGS2TRPV1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044338-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2018-02-15 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044338-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 NPC1 3776/4885PTGS1 1499/4885PTGS2 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback